Ipilimumab/nivolumab

Ipilimumab/nivolumab Reactions 1680, p191 - 2 Dec 2017 Hyperthyroidism, hypothyroidism and hypophysitis : 9 case reports In a retrospective study, 9 patients (4 men and 5 women; aged 50–76-years) were described, who developed hyperthyroidism, hypothyroidism or hypophysitis during treatment with nivolumab alone or nivolumab and ipilimumab [not all dosages stated; routes not stated]. The patients, who had metastatic renal cell carcinoma (1 patient), multiple myeloma (2 patients), metastatic lung cancer (2 patients), metastatic bladder cancer (1 patient), metastatic oesophageal cancer (1 patient) or metastatic melanoma (2 patients), were started on monotherapy with nivolumab 3 mg/kg (6 patients) or nivolumab 1 mg/kg and ipilimumab (2 patients) or nivolumab 1mg/kg for three months followed by 3 mg/kg and ipilimumab (1 patient). Time to first detection of abnormal thyroid blood test after initiation of treatment was 21–249 days. The Anti-TPO antibody was positive in 3 patients (patient 2,5 and 9). The Anti-TG antibody was positive in 5 patients (patient 2,3,4,5 and 7). The TSH levels were less than 0.4 µIU/mL to 56 µIU/mL (ref: more than 0.4 to less than 4.2 µIU/mL). Three patients (patient 1,2 and 7) initially developed hyperthyroidism and then hypothyroidism. Patient 6 and 8 developed only hyperthyroidism and patient 6 was lost to follow-up. The patient 8 also developed hypophysitis, while his hyperthyroidism recovered spontaneously. The remaining four patients developed only hypothyroidism (Patient 3,4,5 and 9) [not all outcomes stated]. Author comment: "The most common endocrine complication observed with [ipilimumab] is hypophysitis, while the most common endocrinopathy reported with PD-1 inhibitors is thyroid disease" "Combination therapy with a PD-1 inhibitor and [ipilimumab] may increase the risk of thyroid disease compared with [nivolumab] alone, as has been reported previously in clinical trials" O’Malley G, et al. RAPID EVOLUTION of THYROID DYSFUNCTION in PATIENTS TREATED with NIVOLUMAB. Endocrine Practice 23: 1223-1231, No. 10, Oct 2017. Available from: URL: http://doi.org/10.4158/EP171832.OR - USA 803284675 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ipilimumab/nivolumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/ipilimumab-nivolumab-yeM0ZAUbdn
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39122-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p191 - 2 Dec 2017 Hyperthyroidism, hypothyroidism and hypophysitis : 9 case reports In a retrospective study, 9 patients (4 men and 5 women; aged 50–76-years) were described, who developed hyperthyroidism, hypothyroidism or hypophysitis during treatment with nivolumab alone or nivolumab and ipilimumab [not all dosages stated; routes not stated]. The patients, who had metastatic renal cell carcinoma (1 patient), multiple myeloma (2 patients), metastatic lung cancer (2 patients), metastatic bladder cancer (1 patient), metastatic oesophageal cancer (1 patient) or metastatic melanoma (2 patients), were started on monotherapy with nivolumab 3 mg/kg (6 patients) or nivolumab 1 mg/kg and ipilimumab (2 patients) or nivolumab 1mg/kg for three months followed by 3 mg/kg and ipilimumab (1 patient). Time to first detection of abnormal thyroid blood test after initiation of treatment was 21–249 days. The Anti-TPO antibody was positive in 3 patients (patient 2,5 and 9). The Anti-TG antibody was positive in 5 patients (patient 2,3,4,5 and 7). The TSH levels were less than 0.4 µIU/mL to 56 µIU/mL (ref: more than 0.4 to less than 4.2 µIU/mL). Three patients (patient 1,2 and 7) initially developed hyperthyroidism and then hypothyroidism. Patient 6 and 8 developed only hyperthyroidism and patient 6 was lost to follow-up. The patient 8 also developed hypophysitis, while his hyperthyroidism recovered spontaneously. The remaining four patients developed only hypothyroidism (Patient 3,4,5 and 9) [not all outcomes stated]. Author comment: "The most common endocrine complication observed with [ipilimumab] is hypophysitis, while the most common endocrinopathy reported with PD-1 inhibitors is thyroid disease" "Combination therapy with a PD-1 inhibitor and [ipilimumab] may increase the risk of thyroid disease compared with [nivolumab] alone, as has been reported previously in clinical trials" O’Malley G, et al. RAPID EVOLUTION of THYROID DYSFUNCTION in PATIENTS TREATED with NIVOLUMAB. Endocrine Practice 23: 1223-1231, No. 10, Oct 2017. Available from: URL: http://doi.org/10.4158/EP171832.OR - USA 803284675 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off